http://biz.yahoo.com/prnews/031014/fltu021_1.html
Press Release Source: Dr. Joan Fallon
Patent Awarded for Pancreatic Enzyme Therapy for ADD, ADHD and Autism
Tuesday October 14, 4:20 pm ET
YONKERS, N.Y., Oct. 14 /PRNewswire/ -- The U.S. Patent and Trademark office has
awarded Dr. Joan Fallon patent # 6,632,429 entitled Methods for Treating
Pervasive Developmental Disorders. The patent covers the use of digestive and
pancreatic enzymes as a treatment for children with ADD, ADHD and Autism.
ADVERTISEMENT
The patent, which will remain in effect until 2019, represents a breakthrough
for children with pervasive developmental disorders including ADD, ADHD and
Autism. Autism is characterized by profound delays in communication and social
interaction and is thought to affect over 1.5 million individuals in the U.S.
ADD and ADHD have a prevalence of between 5 and 10% in the population. It is
estimated that upwards of 10% of the population is medicated for some type of
attention disorder.
Dr. Fallon's invention employs the use of digestive and pancreatic enzymes for
children with these conditions based upon the presence of a low level of
chymotrypsin in the stool. Chymotrypsin is an enzyme secreted by the pancreas
in an inactive form which becomes active in the presence of protein in the
small intestines as well as a favorable pH. Without sufficient protein
digestion, the formation of amino acids, the building blocks of new proteins,
cannot occur. The lack of protein synthesis can underlie a significant
neurological deficit in the child. Fallon's patent demonstrates that the
administration of digestive and pancreatic enzymes produce profound changes in
the autistic symptomotology including increases in social interactions, eye
contact and speech and reductions in repetitive actions and hyperactivity. It
further demonstrates changes in bowel habits including an increase in bowel
control and formed movements.
In the child with ADD and ADHD, the therapy significantly reduces the levels of
medication the child is taking and, in many cases, the child no longer needs
the medication, based upon observed increases in attention.
"The patent recognizes a deficiency in the children with ADD, ADHD and Autism,
and offers a biological solution. Digestive and pancreatic enzymes have been
used safely and effectively for children and adults with cystic fibrosis for
many years," said Dr. Fallon, inventor and patent holder. "I intend to continue
to refine the use of digestive and pancreatic enzymes for these and other
indications. This form of treatment opens new avenues for children and adults
with these debilitating conditions.
Contact: Dr. Joan Fallon 914-779-9300 [email hidden]